View Older Stories
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $92 at BMO Capital on Camzyos Approval
-
BMO Capital Reiterates Outperform Rating on Bristol-Myers Squibb Co. (BMY)
-
Pre-Open Stock Movers 04/18: Casa Systems and Natus Medical Higher; TG Therapeutics and Nektar Lower (more...)
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $81 at BMO Capital
-
BMO Capital Reiterates Bristol-Myers Squibb (BMY) Outperform, Bempeg in Melanoma Was Incremental to BMY's Thesis
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $74 at BMO Capital
-
2022 Product Launches Will Provide Good Foundation for Bristol-Myers Squibb's (BMY) Future Growth, Reiterate Outperform - BMO Capital
-
UPDATE: BMO Capital Starts Bristol-Myers Squibb Co. (BMY) at Outperform
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $66 at BMO Capital
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $63 at BMO Capital
-
Bristol-Myers Squibb (BMY) PT Raised At BMO On Combination With Celgene
-
Bristol-Myers Squibb (BMY) PT Cut To $59 At BMO On Reduced Opdivo Opportunity
-
BMO Capital Reiterates Outperform on Bristol-Myers Squibb (BMY)
-
Bristol-Myers Squibb (BMY) Should Have Support Around $45 - BMO
-
BMO Capital Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
-
UPDATE: Bristol-Myers Squibb Co. (BMY) PT Lowered to $56 at BMO Capital
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $55 at BMO Capital
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $54 at BMO Capital
-
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at BMO Capital
-
(BMY) PT Raised to $51 at BMO Capital
-
BMO Capital Upgrades Bristol-Myers Squibb Co. (BMY) to Market Perform Citing More Balanced Risk/Reward
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $47 at BMO Capital; 'More Headwinds and Uncertainty Ahead'
-
Merck's Keytruda helps lung cancer patients live longer in trial
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $51 at BMO Capital; 'IO NSCLC Complexity Increases'
-
Pfizer (PFE) Not Hungry for a Large Deal - BMO
-
Pfizer (PFE) Should Buy Biogen (BIIB) Instead - BMO
-
Pre-Open Stock Movers 07/31: (DVAX) (CHTR) (DAN) Higher; (HTZ) (CLVS) (ICPT) Lower (more...)
-
Bristol-Myers Squibb (BMY): IO Uncertainty Drives PT Decrease - BMO
-
Bristol-Myers Squibb's (BMY) Call Didn't Alleviate Concerns - BMO
-
If AstraZeneca (AZN) Soriot Rumors are True, It Becomes a Pfizer (PFE) Acquisition Target Again; Negative for Bristol-Myers (BMY)
-
BMO Capital Downgrades Bristol-Myers Squibb Co. (BMY) to Underperform
-
Bristol-Myers Squibb (BMY): Takeout Unlikely - BMO
-
BMO Capital Maintains Market Perform Rating and $45 PT on Bristol-Myers Squibb (BMY) Following Results from CM-067 Study; Expectations to Decline for Opdivo + Yervoy
-
BMO Capital Opines on Possible Bristol-Myers (BMY) Acquisition
-
Bristol-Myers Squibb (BMY) Takeover Less Likely Following Pfizer (PFE) Call - BMO
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $47 at BMO Capital; See Much Uncertainty and Increased Risk
-
Bristol-Myers Squibb Co. (BMY): Execution Risk Higher - BMO
-
AstraZeneca (AZN) MYSTIC Change Positive for Merck (MRK), Less so for Bristol-Myers Squibb (BMY) - BMO
-
Complete Donald Trump Stock Impact Guide
-
Major Pharma Got a Major Win Last Night - BMO
-
Notable 52-Week Highs and Lows 10/24: (TMUS) (MSFT) (GLW) High; (TDW) (WIT) (BMY) Low
-
BMO Capital Remains Cautious on Bristol-Myers Squibb (BMY) Despite Decline; PT Lowered to $56
-
Pre-Open Stock Movers 10/10: (IPCI) (TSRO) (MYL) Higher; (TWTR) (BMY) (DOV) Lower (more...)
-
Bristol-Myers Squibb (BMY): Roche Study Highlights Increasing Competition - BMO
-
Bristol-Myers (BMY) Opdivo Trial Miss a 'Seismic Event', BMO Capital Says (MRK)
-
BMO Capital Downgrades Bristol-Myers Squibb Co. (BMY) to Market Perform
-
Bristol-Myers (BMY) JP Morgan Update 'Incrementally Positive', Negative for Merck (MRK) - BMO Capital
-
Notable Analyst Rating Changes 9/29: (MU) (BMY) (RJET) Upgraded; (SCCO) (VSTM) (SQNM) Downgraded
-
BMO Positive on Bristol-Myers Squibb's (BMY) Receipt of FDA Breakthrough Therapy Designation for Opdivo
-
Streetinsider.com's Hot Lunchtime Reads 7/20: (AAPL) (BUD) (TSLA) (BMY)